Agenda
The IBC 2024 Meeting will feature three key topic tracks:
MBL-CLL/Low-grade Lymphoma
*All times are in CET
Mar
Thu 14
Welcome and introductions – Plenary
Keynote Lecture
The best cancer is the cancer that never happened: Phil Castle
Plenary Session #1: Early detection and screening – should we screen everyone or people at risk, germline risks? (Part I)
- Origin of the precursor state in MM: Rafael Fonseca
- CHIP/CCUS Natural History Protocol: TBC
- Germline predisposition in CLL: Anna Schuh
- Germline predisposition to CH: Lucy Godley
- Genomic evolution from MGUS to MM- Francesco Maura
Panel Discussion (20 mins): Who should be screened for blood cancer precursors? Population research strategies
Break
Breakout session #1
Biology of precursor CLL and FL conditions
- Optimizing the Diagnostic Criteria for MBL (is there a better way to define MBL/lymphoid CHIP, perhaps not by cell number but by mutational profile): Aswin Sekar
Role of MBL in the etiology of CLL
- Identification of specific genetic drivers of CLL long before diagnosis: Anton Langerak
- Familial CLL and MBL with common genetic aberrations in families: Hendrik Veelken
Lymphoma
- Modelling B-cell state transitions to aid design of lymphoma therapies: Ari Melnick
- B-cells breaking bad, generating pathogenic autoantibodies: TBC
Welcome reception
Mar
Fri 15
Overview of Day 2 &
Keynote lecture #2
Title TBC: Michael Stratton
Plenary Session #2: Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical (Part I)
- Genomic evolution in MM and other cancers: Gad Getz
- Mechanisms of disease progression from MBL to CLL: Cathy Wu
- Utility of NGS to differentiate MN from other cytopenic conditions: TBC
- Immune regulation in disease progression from MGUS to MM: Irene Ghobrial
Panel discussion: Defining what is a precancerous condition in blood cancers
Keynote Lecture #3
Risk stratification/biomarkers: Peter Campbell
Break
Plenary Session #3
Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical biomarkers (Part 2)
- Immune based stratification: Madhav Dhodapkar
- CHIP: George Vassiliou
- Can we envisage immune biomarkers as tools for predicting risk of premalignant to malignant indolent lymphoma transition?: Stephen Ansell
Panel discussion: What is the risk of blood cancer precursors – clinical tools for risk stratification
Breakout session #2
- Tracing founder mutations/translocations – should we be screening for lymphomas: Sandrine Roulland
- Modelling early FL biology in murine models: Dinis Calado
- Bellinzona – ctDNA as a biomarker for predicting progression/screening in lymphoma: Davide Rossi
Lymphoma
Biology of indolent to aggressive lymphomas
- FL to transformed FL, can we predict: Jessica Okosun
- Other indolent entities (MZL) to DLBCL – what can we learn?: Sílvia Beà
- Significance of CLL genetic prognostic markers in MBL including their new paper on TP53: Susan Slager
- Indolent to aggressive: Progression of CLL and FL RS-CLL-> Richter’s: Erin Parry
Lunch
Plenary Session #4
Interception – endpoint of trials, which patient population, diverse populations (Part I)
- Early intervention in SMM: María-Victoria Mateos
- Early intervention approaches in CLL: Matthew Davids
- Novel immune-therapeutics in SMM: Omar Nadeem
- CHIP clinic: Eric Padron
- PIMMS study (decentralized trial of ivosidenib in CCUS): Kelly Bolton
Panel discussion: Patient population considerations for blood cancer precursors and clinical trial design
Break
Breakout Session #3
- Infection risk and vaccine efficacy in MBL and CLL: TBC
- CLL NeoVax trial update: Inhye Ahn
- PreVent-ACaLL trial and an overview of using machine-learning algorithms to assess risk of infection in CLL: Carsten Niemann
- Data on the translational studies from the patients on the trial: Marwan Kwok
Mar
Sat 16
Keynote lecture #4: Interception – Endpoints of trials, trial design, which patient population, diverse populations
FDA endpoints and trial designs in precursor conditions: Nicole Gormley
Plenary Session: #5 – panel
Stakeholder panel of pharma, foundation, FDA and EMEA
Moderator: Kenneth Anderson
Break
Plenary Session: Workshop Outcomes and Initiatives – Key outcomes and action of breakout
- MM/SMM/MGUS: Shaji Kumar
- CHIP/MDS: George Vasilliou
- MBL-CLL/Low-grade Lymphoma: Matthew Davids/Jessica Okosun
Summary and conclusion
CHIP/MDS
*All times are in CET
Mar
Thu 14
Welcome and introductions – Plenary
Keynote Lecture
The best cancer is the cancer that never happened: Phil Castle
Plenary Session #1: Early detection and screening – should we screen everyone or people at risk, germline risks? (Part I)
- Origin of the precursor state in MM: Rafael Fonseca
- CHIP/CCUS Natural History Protocol: TBC
- Germline predisposition in CLL: Anna Schuh
- Germline predisposition to CH: Lucy Godley
- Genomic evolution from MGUS to MM- Francesco Maura
Panel Discussion (20 mins): Who should be screened for blood cancer precursors? Population research strategies
Break
Breakout session #1
- Requirement for CHIP mutations in pre-leukemia vs. frank AML with focus on DNMT3A: Ravi Majeti
CH in solid tumors and t-MN risk
- Talk title TBC: Caroline Watson
- CH in autologous stem cell transplant recipients: Coleman Lindsley
CH dynamics and progression
Mitochondrial mutation tracking and clonal dynamics: TBC
Welcome reception
Mar
Fri 15
Overview of Day 2 &
Keynote lecture #2
Title TBC: Michael Stratton
Plenary Session #2: Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical (Part I)
- Genomic evolution in MM and other cancers: Gad Getz
- Mechanisms of disease progression from MBL to CLL: Cathy Wu
- Utility of NGS to differentiate MN from other cytopenic conditions: TBC
- Immune regulation in disease progression from MGUS to MM: Irene Ghobrial
Panel discussion: Defining what is a precancerous condition in blood cancers
Keynote Lecture #3
Risk stratification/biomarkers: Peter Campbell
Break
Plenary Session #3
Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical biomarkers (Part 2)
- Immune based stratification: Madhav Dhodapkar
- CHIP: George Vassiliou
- Can we envisage immune biomarkers as tools for predicting risk of premalignant to malignant indolent lymphoma transition?: Stephen Ansell
Panel discussion: What is the risk of blood cancer precursors – clinical tools for risk stratification
Breakout session #2
- Clonal hematopoiesis in inflammatory disease (CH in VEXAS syndrome): Mrinal Patnaik
- Prediction models in CH: Muxin Gu
- Talk title TBC: Siddhartha Jaiswal
- CH and liver disease: Waihay Wong
CH in Specific contexts
- MN risk in sickle cell disease and other hereditary hemolytic anemias: Lachelle Weeks
- Talk title TBC
Lunch
Plenary Session #4
Interception – endpoint of trials, which patient population, diverse populations (Part I)
- Early intervention in SMM: María-Victoria Mateos
- Early intervention approaches in CLL: Matthew Davids
- Novel immune-therapeutics in SMM: Omar Nadeem
- CHIP clinic: Eric Padron
- PIMMS study (decentralized trial of ivosidenib in CCUS): Kelly Bolton
Panel discussion: Patient population considerations for blood cancer precursors and clinical trial design
Break
Breakout Session #3
- Decitabine/cedazuridine in high risk CCUS: Maximilian Stahl
- Therapeutic vulnerabilities in CH: Siddhartha Kar
- Trial in CH: TBC
Mar
Sat 16
Keynote lecture #4: Interception – Endpoints of trials, trial design, which patient population, diverse populations
FDA endpoints and trial designs in precursor conditions: Nicole Gormley
Plenary Session: #5 – panel
Stakeholder panel of pharma, foundation, FDA and EMEA
Moderator: Kenneth Anderson
Break
Plenary Session: Workshop Outcomes and Initiatives – Key outcomes and action of breakout
- MM/SMM/MGUS: Shaji Kumar
- CHIP/MDS: George Vasilliou
- MBL-CLL/Low-grade Lymphoma: Matthew Davids/Jessica Okosun
Summary and conclusion
MM/SMM/MGUS
*All times are in CET
Mar
Thu 14
Welcome and introductions – Plenary
Keynote Lecture
The best cancer is the cancer that never happened: Phil Castle
Plenary Session #1: Early detection and screening – should we screen everyone or people at risk, germline risks? (Part I)
- Origin of the precursor state in MM: Rafael Fonseca
- CHIP/CCUS Natural History Protocol: TBC
- Germline predisposition in CLL: Anna Schuh
- Germline predisposition to CH: Lucy Godley
- Genomic evolution from MGUS to MM- Francesco Maura
Panel Discussion (20 mins): Who should be screened for blood cancer precursors? Population research strategies
Break
Breakout session #1
- The iSTOPMM study: Sigurður Kristinsson
- GWAS in monoclonal gammopathies: Celine Vachon
- The PROMISE study and other screening efforts so far: Elizabeth O’Donnell
Panel discussion: Designing early detection studies in MM
Welcome reception
Mar
Fri 15
Overview of Day 2 &
Keynote lecture #2
Title TBC: Michael Stratton
Plenary Session #2: Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical (Part I)
- Genomic evolution in MM and other cancers: Gad Getz
- Mechanisms of disease progression from MBL to CLL: Cathy Wu
- Utility of NGS to differentiate MN from other cytopenic conditions: TBC
- Immune regulation in disease progression from MGUS to MM: Irene Ghobrial
Panel discussion: Defining what is a precancerous condition in blood cancers
Keynote Lecture #3
Risk stratification/biomarkers: Peter Campbell
Break
Plenary Session #3
Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical biomarkers (Part 2)
- Immune based stratification: Madhav Dhodapkar
- CHIP: George Vassiliou
- Can we envisage immune biomarkers as tools for predicting risk of premalignant to malignant indolent lymphoma transition?: Stephen Ansell
Panel discussion: What is the risk of blood cancer precursors – clinical tools for risk stratification
Breakout session #2
- Risk stratifying MGUS: Angela Dispenzieri
- Updates to 20/2/20 and other models including PANGAEA: Shaji Kumar
- Circulating tumor cells and other novel biomarkers to be added to the current models: Romanos Sklavenitis-Pistofidis
- Talk title TBC
Lunch
Plenary Session #4
Interception – endpoint of trials, which patient population, diverse populations (Part I)
- Early intervention in SMM: María-Victoria Mateos
- Early intervention approaches in CLL: Matthew Davids
- Novel immune-therapeutics in SMM: Omar Nadeem
- CHIP clinic: Eric Padron
- PIMMS study (decentralized trial of ivosidenib in CCUS): Kelly Bolton
Panel discussion: Patient population considerations for blood cancer precursors and clinical trial design
Break
Breakout Session #3
- Non-drug approaches to intervention: Urvi Shah
- Prevention studies in MGUS and SMM: Catherine Marinac
- Endpoints for interception trials: Jesús San-Miguel
Mar
Sat 16
Keynote lecture #4: Interception – Endpoints of trials, trial design, which patient population, diverse populations
FDA endpoints and trial designs in precursor conditions: Nicole Gormley
Plenary Session: #5 – panel
Stakeholder panel of pharma, foundation, FDA and EMEA
Moderator: Kenneth Anderson
Break
Plenary Session: Workshop Outcomes and Initiatives – Key outcomes and action of breakout
- MM/SMM/MGUS: Shaji Kumar
- CHIP/MDS: George Vasilliou
- MBL-CLL/Low-grade Lymphoma: Matthew Davids/Jessica Okosun
Summary and conclusion
